CA-THE-OPEN-GROUP
6.1.2022 10:02:04 CET | Business Wire | Press release
Effective January 1st, Energistics Consortium, Inc. is now an affiliate of The Open Group®, a global consortium that enables the achievement of business objectives through technology standards. Energistics remains a separate entity, with The Open Group assuming control of Energistics operations, in a move which will enable broader community access, more efficient collaboration, and stronger standards evolution in line with the global energy transition.
Having proudly served the industry for over thirty years, Energistics is also a long-standing member of The Open Group OSDU™ Forum, and in October 2018 became the first non-operator company to be invited to join the Forum. Its WITSML™ , RESQML™ , PRODML™ , and ETP standards have become universal in the industry and form a critical component of the OSDU Data Platform.
Development will continue in Energistics Special Interest Groups (SIGs) to ensure the standards remain a vibrant part of the Energy community. Most recently, Energistics Transfer Protocol v1.2 was released in September 2021, and a consolidated Release Candidate for new versions of RESEQML, PRODML, and WITSML was made available in December 2021.
This work will support both the wider industry and the ongoing development of the OSDU Data Platform and standards for analyzing legacy subsurface energy data as well as new energy data from wind, geothermal, hydrogen, photovoltaic sources, and carbon capture, utilization, and storage data sources.
“As Energistics starts an exciting new chapter in its development, we want to thank the more than 3,500 upstream subject matter experts, from over 115 member companies, who have contributed to its development over the last thirty years,” said Ross Philo, CEO of Energistics. “We are also particularly grateful to our operational staff, who have served the industry with outstanding dedication. They have ensured a smooth transition for our members, and we wish them all the best in their next adventure.”
Today’s transition of governance reflects the significant overlap between Energistics and The Open Group OSDU Forum, with 42 of the 220 current Forum members also being Energistics members. Retaining its own board, the work of Energistics will now be overseen by members of both organizations alongside The Open Group itself.
“The relationship between Energistics and The Open Group has been a long and fruitful one, and this is the right next step for our organizations,” adds Steve Nunn, CEO and President of The Open Group. “Bringing the knowledge and capabilities of The Open Group OSDU Forum and the Energistics SIGs closer together means that we will continue to lead the charge in data exchange standards for the industry, while also opening doors to a broader community for both organizations. We are committed to ensuring that the Energistics standards continue to evolve, thrive, and enable cross-discipline integration of industry data.”
- ENDS -
About Energistics
Energistics is the leading upstream oil and gas industry's data standards body. We are a global, non-profit consortium established over 30 years ago to bring together industry professionals in a neutral and collaborative environment to develop and deploy open data exchange standards and to address oil and gas information sharing challenges. Our members consist of international and nationalized oil companies, oilfield service companies, hardware and software vendors, system integrators, regulatory agencies, and the global standards user community. For more information, visit our website at www.energistics.org .
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .
About The Open Group OSDU Forum
The Open Group OSDU Forum is developing the Open-Source Software OSDU Data Platform and associated standards that enables the Energy industry to develop the transformational technology implementation to support the world's changing Energy needs. The Open Group OSDU Forum has over 225 member organizations and over 1900 subscribers worldwide. Membership in The Open Group OSDU Forum is available to all energy stakeholders including international and nationalized oil companies, new energy providers, application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found at www.osduforum.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
